Literature DB >> 20001878

A new paradigm for treating infections: "go hard and go home".

Jeffrey Lipman1, Rob Boots.   

Abstract

There is now significant evidence that initial use of the correct antibiotic saves more lives than virtually all other intensive care therapy. This means covering all possible causative organisms with the initial empirical choice. For nosocomial sepsis, broad-spectrum antibiotics must be started as soon as the relevant samples have been taken for culture, with de-escalation of therapy targeted to the causative organisms when results and susceptibilities are available. There is an international trend to use shorter antibiotic courses. Pseudomonas pneumonia probably needs a 7-10 day course. In our ICU, provided the infection source is controlled, we seldom use antibiotic courses longer than 7 days. Evaluation of the kill characteristics of antibiotics in experimental models suggests that different classes of antibiotics should have different dosing regimens. For Beta- lactam antibiotics, the kill characteristic is almost entirely related to the time that tissue and plasma levels exceed a certain threshold, with no significant post-antibiotic effect, particularly against gram-negative organisms. Kill characteristics of other antibiotics, such as aminoglycosides, relate to adequate peak concentrations and a significant post-antibiotic effect. Clinically, these kill characteristics translate into the need for appropriate doses of the various antibiotics in patients with sepsis. We have shown that some patients with normal serum creatinine levels have very high creatinine clearance rates; in ICU patients with sepsis, blood pressure and tissue perfusion are maintained with large fluid loads and inotropic agents, thereby raising creatinine clearance. High clearances produce low trough concentrations of antibiotic, with important implications for underdosing and the development of antibiotic resistance. The new paradigm for treating sepsis, particularly nosocomial sepsis, is: get it right the first time, hit hard up front, and use large doses of broad-spectrum antibiotics for a short period.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20001878

Source DB:  PubMed          Journal:  Crit Care Resusc        ISSN: 1441-2772            Impact factor:   2.159


  4 in total

1.  Delay in the administration of appropriate antimicrobial therapy in Staphylococcus aureus bloodstream infection: a prospective multicenter hospital-based cohort study.

Authors:  A J Kaasch; S Rieg; J Kuetscher; H-R Brodt; T Widmann; M Herrmann; C Meyer; T Welte; P Kern; U Haars; S Reuter; I Hübner; R Strauss; B Sinha; F M Brunkhorst; M Hellmich; G Fätkenheuer; W V Kern; H Seifert
Journal:  Infection       Date:  2013-03-29       Impact factor: 3.553

Review 2.  Surviving Sepsis in the Intensive Care Unit: The Challenge of Antimicrobial Resistance and the Trauma Patient.

Authors:  Yogandree Ramsamy; Timothy C Hardcastle; David J J Muckart
Journal:  World J Surg       Date:  2017-05       Impact factor: 3.352

3.  Macrolides and community-acquired pneumonia: is quorum sensing the key?

Authors:  Matt P Wise; David W Williams; Michael A O Lewis; Paul J Frost
Journal:  Crit Care       Date:  2010-07-20       Impact factor: 9.097

Review 4.  Key Components for Antibiotic Dose Optimization of Sepsis in Neonates and Infants.

Authors:  Tamara van Donge; Julia A Bielicki; John van den Anker; Marc Pfister
Journal:  Front Pediatr       Date:  2018-10-29       Impact factor: 3.418

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.